Biological mechanism profiling using an annotated compound library.

[1]  Rascon.  [The National Cancer Institute]. , 1953, Boletin cultural e informativo - Consejo General de Colegios Medicos de Espana.

[2]  S. Aaronson,et al.  In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. , 1973, Journal of the National Cancer Institute.

[3]  Barry H. Smith,et al.  A continuous tumor‐cell line from a human lung carcinoma with properties of type II alveolar epithelial cells , 1976, International journal of cancer.

[4]  A. J. Garrett,et al.  Characteristics of a serially propagated human diploid cell designated MRC-9. , 1979, Journal of biological standardization.

[5]  A. Jimenez,et al.  The mode of action of the antitumor drug bouvardin, an inhibitor of protein synthesis in eukaryotic cells , 1982, FEBS letters.

[6]  Mode and kinetics of DNA binding of the anti-tumour agent bisantrene. , 1987, Anti-cancer drug design.

[7]  Y. Suzuki,et al.  Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. H. Spencer,et al.  Organization of repetitive DNAs in the guinea pig genome. , 1988, Advances in enzyme regulation.

[9]  B. Long,et al.  Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners. , 1988, Advances in enzyme regulation.

[10]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[11]  R. Sternglanz,et al.  Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. , 1988, Molecular pharmacology.

[12]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[13]  J. Wang,et al.  Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. , 1989, Cancer research.

[14]  J. Knoben,et al.  An overview of the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations. , 1990, American journal of hospital pharmacy.

[15]  L. Liu,et al.  Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. , 1990, Cancer research.

[16]  J. Champoux,et al.  Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin. , 1992, Cancer research.

[17]  Michel Petitjean,et al.  Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds , 1992, J. Chem. Inf. Comput. Sci..

[18]  X M Wang,et al.  A new microcellular cytotoxicity test based on calcein AM release. , 1993, Human immunology.

[19]  E. Estey,et al.  Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. , 1993, Seminars in oncology.

[20]  T. Mitchison,et al.  Towards a pharmacological genetics. , 1994, Chemistry & biology.

[21]  Teuvo Kohonen,et al.  Self-Organizing Maps , 2010 .

[22]  Z. Darżynkiewicz,et al.  Induction of Apoptosis by Camptothecin and Topotecan , 1996, Annals of the New York Academy of Sciences.

[23]  G. S. Johnson,et al.  An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.

[24]  S. Schreiber.  Chemical genetics resulting from a passion for synthetic organic chemistry. , 1998, Bioorganic & medicinal chemistry.

[25]  M. Piccart,et al.  Paclitaxel activity, dose, and schedule: data from phase III trials in metastatic breast cancer. , 1999, Seminars in oncology.

[26]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[27]  Michael E. Johnson,et al.  Multiple Novel Inhibitors of the NorA Multidrug Transporter of Staphylococcus aureus , 1999, Antimicrobial Agents and Chemotherapy.

[28]  D. Botstein,et al.  Exploring the new world of the genome with DNA microarrays , 1999, Nature Genetics.

[29]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[30]  Stuart L. Schreiber,et al.  Chemical Genetic and Genomic Approaches Reveal a Role for Copper in Specific Gene Activation , 1999 .

[31]  J. Weinstein,et al.  Molecular targets in cancer drug discovery: cell-based profiling. , 2000, Current pharmaceutical design.

[32]  J. Champoux.  Structure‐Based Analysis of the Effects of Camptothecin on the Activities of Human Topoisomerase I , 2000, Annals of the New York Academy of Sciences.

[33]  Thomas C. Rindflesch,et al.  EDGAR: extraction of drugs, genes and relations from the biomedical literature. , 1999, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.

[34]  P. D'Arpa,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.

[35]  J. Dowling,et al.  Small molecule developmental screens reveal the logic and timing of vertebrate development. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[37]  Jae K. Lee,et al.  Mining and Visualizing Large Anticancer Drug Discovery Databases , 2000, J. Chem. Inf. Comput. Sci..

[38]  B. Stockwell.  Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.

[39]  Ferenc Darvas,et al.  Diversity Measures for Enhancing ADME Admissibility of Combinatorial Libraries , 2000, J. Chem. Inf. Comput. Sci..

[40]  Mark Waltham,et al.  Mining and Visualizing Large Anticancer Drug Discovery Databases. , 2000 .

[41]  W. Hevers,et al.  Coupling between agonist and chloride ionophore sites of the GABA(A) receptor: agonist/antagonist efficacy of 4-PIOL. , 2000, European journal of pharmacology.

[42]  B. Stockwell,et al.  Frontiers in chemical genetics. , 2000, Trends in biotechnology.

[43]  Antiproliferative activity and mechanism of action of DZ-3358, a novel pyrimidinyl pyrazole derivative. , 2000, Anticancer research.

[44]  M. Kombrabail,et al.  Effect of phloretin on ionophore mediated electroneutral transmembrane translocations of H(+), K(+) and Na(+) in phospholipid vesicles. , 2001, Biochimica et biophysica acta.

[45]  T. Jenssen,et al.  A literature network of human genes for high-throughput analysis of gene expression , 2001 .

[46]  E. Skjerve,et al.  Reduced incidence of Clostridium perfringens-associated lesions and improved performance in broiler chickens treated with normal intestinal bacteria from adult fowl. , 2001, Avian diseases.

[47]  M. Miller,et al.  Chemistry and chemical biology of taxane anticancer agents. , 2001, The chemical record.

[48]  T. Cooper,et al.  Effects of the ion-channel blocker quinine on human sperm volume, kinematics and mucus penetration, and the involvement of potassium channels. , 2001, Molecular human reproduction.

[49]  Yuji Kohara,et al.  Large-scale analysis of gene function in Caenorhabditis elegans by high-throughput RNAi , 2001, Current Biology.

[50]  B. Druker,et al.  STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.

[51]  Robert A. Weinberg,et al.  Enumeration of the Simian Virus 40 Early Region Elements Necessary for Human Cell Transformation , 2002, Molecular and Cellular Biology.

[52]  William C Hahn,et al.  Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.